Hu Wenhao, Yu Jiayi, Huang Yong, Hu Fanqi, Zhang Xuesong, Wang Yan
Department of Orthopedics, Chinese PLA General Hospital, Beijing, China.
Department of Renal cancer and Melanoma, Peking University Cancer Hospital, Beijing, China; Department of Orthopedics, Chinese PLA General Hospital, Beijing, China.
Transl Oncol. 2018 Apr;11(2):444-449. doi: 10.1016/j.tranon.2018.01.010. Epub 2018 Feb 22.
The inflammatory microenvironment plays a critical role in the development and progression of malignancies. In the present study, we aimed to evaluate the prognostic value of lymphocyte-related inflammation and immune-based prognostic scores in patients with chordoma after radical resection, including the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII). A total of 172 consecutive patients with chordoma who underwent radical resection were reviewed. R software was used to randomly select 86 chordoma patients as a training set and 86 chordoma patients as a validation set. Potential prognostic factors were also identified, including age, sex, tumor localization, KPS, Enneking stage, tumor size, and tumor metastasis. Overall survival (OS) was calculated using the Kaplan-Meier method and multivariate Cox regression analyses. NLR, PLR, SII, Enneking stage, tumor differentiation and tumor metastasis were identified as significant factors from the univariate analysis in both the training and validation sets and were subjected to multivariate Cox proportional hazards analysis. The univariate analysis showed that NLR ≥1.65, PLR ≥121, and SII ≥370×10/L were significantly associated with poor OS. In the multivariate Cox proportional hazard analysis, SII, Enneking stage and tumor metastasis were significantly associated with OS. As noninvasive, low-cost, reproducible prognostic biomarkers, NLR, PLR and SII could help predict poor prognosis in patients with chordoma after radical resection. This finding may contribute to the development of more effective tailored therapy according to the characteristics of individual tumors.
炎症微环境在恶性肿瘤的发生和发展中起着关键作用。在本研究中,我们旨在评估淋巴细胞相关炎症和基于免疫的预后评分在脊索瘤患者根治性切除后的预后价值,包括中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、单核细胞与淋巴细胞比值(MLR)和全身免疫炎症指数(SII)。回顾性分析了172例连续接受根治性切除的脊索瘤患者。使用R软件随机选择86例脊索瘤患者作为训练集,86例脊索瘤患者作为验证集。还确定了潜在的预后因素,包括年龄、性别、肿瘤定位、KPS、Enneking分期、肿瘤大小和肿瘤转移。采用Kaplan-Meier法和多因素Cox回归分析计算总生存期(OS)。在训练集和验证集的单因素分析中,NLR、PLR、SII、Enneking分期、肿瘤分化和肿瘤转移均被确定为显著因素,并进行多因素Cox比例风险分析。单因素分析显示,NLR≥1.65、PLR≥121和SII≥370×10⁹/L与较差的OS显著相关。在多因素Cox比例风险分析中,SII、Enneking分期和肿瘤转移与OS显著相关。作为无创、低成本、可重复的预后生物标志物,NLR、PLR和SII有助于预测脊索瘤患者根治性切除后的不良预后。这一发现可能有助于根据个体肿瘤特征制定更有效的个体化治疗方案。